-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

621.O4.6 621. Lymphomas: Translational—Molecular and Genetic: Single Cell, Microenvironment, and Treatment Resistance

Symposia: Lymphomas: Translational—Molecular and Genetic Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Fundamental Science, adult, Translational Research, Lymphomas, non-Hodgkin lymphoma, elderly, genomics, B Cell lymphoma, bioinformatics, T Cell lymphoma, Diseases, indolent lymphoma, aggressive lymphoma, immunology, Lymphoid Malignancies, computational biology, Biological Processes, emerging technologies, Technology and Procedures, molecular biology, Study Population, profiling, Human, pathogenesis, machine learning, omics technologies
Saturday, December 10, 2022: 4:00 PM-5:30 PM
La Nouvelle Orleans Ballroom C (Ernest N. Morial Convention Center)
Moderators:
Jessica Okosun, PhD, Barts Hospital and Robert Kridel, MD, Princess Margaret Cancer Center
Disclosures:
No relevant conflicts of interest to declare.
4:00 PM

Megan Perrett1*, Lucy Pickard, MB ChB1*, Emil Kumar, MB BChir PhD1*, Giuseppe Palladino, PhD1*, Faraz Khan, PhD2*, Carina Edmondson, PhD1*, Connor Knight2*, Edward Poynton1*, Janet Matthews1*, Shamzah Araf, MRCP, MBBS, PhD1*, Andrew James Clear, BSc1*, Maria Calaminici, MD, PhD1*, John G. Gribben, MD, DSc, FRCPath3, Hamish King, PhD4*, Mirjana Efremova, PhD2*, Jun Wang, PhD2* and Jessica Okosun, PhD1

1Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
2Centre for Cancer Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
3Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
4Epigenetics and Development, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia

4:15 PM

Clementine Sarkozy, MD, PhD1,2*, Shaocheng Wu3*, Katsuyoshi Takata, MD, PhD4*, Tomohiro Aoki, MD, PhD4, Susana Ben-Neriah, MSc4*, Katy Milne5*, Brad H Nelson5*, Andrew P. Weng, MD6, David W. Scott, PhD, MD, FRACP, FRCPA7,8, Jeffrey W. Craig, MD, PhD9*, Christian Steidl4,10* and Andrew Roth3*

1Institut Curie, Saint Cloud, France, Saint Cloud, France
2Hematology Department, Institut Curie, Saint Cloud, France
3BC Cancer, Department of Molecular Oncology, Vancouver, BC, Canada
4Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada
5Deeley Research Centre, BC Cancer, Victoria, BC, Canada
6Terry Fox Laboratory, BC Cancer Agency, Vancouver, BC, Canada
7Centre for Lymphoid Cancer, Department of Medical Oncology, BC Cancer and University of British Columbia, Vancouver, BC, Canada
8British Columbia Cancer Agency, Vancouver, BC, Canada
9BC Cancer Centre for Lymphoid Cancer and Department of Pathology and Laboratory Medicine, Vancouver, BC, Canada
10Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada

4:30 PM

Donnacha Fitzgerald, BPharm1,2,3*, Tobias Roider, MD3,4,5*, Marc-A. Baertsch, MD6,7*, Harald Vöhringer, PhD1,4*, Mareike Knoll8*, Bettina Budeus, PhD9*, Artur Kibler, PhD9*, Anna Mathioudaki, MSc10,11*, Léandra Caillé5*, Linsha Li, MSc4*, Johannes Mammen1,3*, Marc Seifert, PhD12*, Wolfgang Huber, PhD3,4* and Sascha Dietrich, M.D.3,4,5

1Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany
2Molecular Medicine Partnership Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany
3Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany
4European Molecular Biology Laboratory (EMBL), Heidelberg, Germany
5Internal Medicine V - Hematology, Oncology & Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
6Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
7School of Medicine, Department of Microbiology and Immunology, Stanford University, Stanford, CA
8Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
9Institute of Cellbiology, Essen, DEU
10Structural and Computational Biology Unit, EMBL, Heidelberg, Germany
11Department of Medicine V, Hematology, Oncology and Rheumatology,, University Hospital Heidelberg, Heidelberg, Germany
12Group Molecular Genetics, Essen University Hospital, Essen, Germany

4:45 PM

Hannah Dorando, BS1*, Jared Andrews, PhD1*, Nicholas Borcherding, MD, PhD2*, Chaz Quinn, MS1*, Jennifer Schmidt, MS1*, Jahnavi Aluri, PhD3*, Megan Cooper, MD, PhD4*, Amy C.M. Musiek, MD5*, Neha Mehta-Shah, MD, MSCI6 and Jacqueline E. Payton, MD, PhD1

1Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO
2Washington University School of Medicine, ST LOUIS, MO
3Washington University School of Medicine, Saint Louis, MO
4Department of Pediatrics, Washington University School of Medicine, Saint Louis, MO
5Department of Medicine, Division of Dermatology, Washington University School of Medicine, Saint Louis, MO
6Division of Oncology, Washington University School of Medicine, St. Louis, MO

5:00 PM

Makoto Yamagishi, PhD1*, Yuta Kuze2*, Makoto Nakashima, Ph.D.1*, Seiichiro Kobayashi, M.D., Ph.D.3, Satoko Morishima, M.D., Ph.D.4*, Toyotaka Kawamata, M.D., Ph.D.5*, Junya Makiyama, M.D., Ph.D.6*, Kazumi Abe2*, Kiyomi Imamura2*, Eri Watanabe7*, Kazumi Tsuchiya7*, Isao Yasumatsu8*, Gensuke Takayama, PhD9*, Kazumi Ito, D.V.M., Ph.D.10*, Yasuhito Nannya, M.D., Ph.D.5, Arinobu Tojo, M.D., Ph.D.11, Toshiki Watanabe, M.D., Ph.D.12*, Shinji Tsutsumi, Ph.D.10*, Yutaka Suzuki, Ph.D.13* and Kaoru Uchimaru, M.D., Ph.D.1*

1Laboratory of Tumor Cell Biology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan
2Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Chiba, Japan
3Department of Hematology, Kanto Rosai Hospital, Kanagawa, Japan
4Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan
5Department of Hematology/Oncology, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
6Department of Hematology, Sasebo City General Hospital, Nagasaki, Japan
7IMSUT Clinical Flow Cytometry Laboratory, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
8Organic Synthesis Department, Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan
9Translational Science I, Daiichi Sankyo Co., Ltd., Shinagawa-Ku, Japan
10Translational Science I, Daiichi Sankyo Co., Ltd., Tokyo, Japan
11Tokyo Medical and Dental University, Tokyo, Japan
12Department of Advanced Medical Innovation, St. Marianna University Graduate School of Medicine, Kanagawa, Japan
13Laboratory of Systems Genomics, Department of Computational Biology and Medical Sciences, The University of Tokyo, Tokyo, Japan

5:15 PM

Marine Baron1,2*, Karim Labreche, PhD3*, Amira Bouzidi, PhD4*, Marianne Veyri5*, Nathalie Désiré3*, Véronique Leblond, MD, PhD1*, Florence Coulet6*, Pierre-Yves Boelle3*, Fatou Seck Thiam3*, Damien Roos-Weil, MD, PhD1*, Frédéric Charlotte, MD7*, Frederic Davi, MD, PhD8*, Elsa Poullot, MD9*, Alice Rousseau2*, Corinne Haioun, MD, PhD10, Jean-Philippe Spano, MD, PhD5*, Brigitte Autran, MD, PhD2*, Choquet Sylvain, MD11* and Amélie Guihot, MD, PhD2*

1Department of Clinical Haematology, Sorbonne Université, AP-HP, Pitié-Salpêtrière Hospital, Paris, France
2Department of Immunology, Sorbonne Université, INSERM U1135, CIMI, AP-HP, Pitié-Salpêtrière Hospital, Paris, France
3Department of Bioinformatics, Sorbonne Université, INSERM, Pierre Louis Institute of Epidemiology and Public Health, Paris, France
4Department of Endocrine Biochemistry and Oncology, Sorbonne Université, INSERM, Research Unit on Cardiovascular and Metabolic Disease UMR ICAN, AP-HP, Pitié-Salpêtrière Hospital, Paris, France
5Department of Clinical Oncology, Sorbonne Université, AP-HP, Pitié-Salpêtrière Hospital, Paris, France
6Department of medical genetics, Sorbonne Université, INSERM, Saint-Antoine Research Center, Microsatellites Instability and Cancer, CRSA, AP-HP, Pitié-Salpêtrière Hospital, Paris, France
7Department of Pathology, Sorbonne Université, APHP, Pitié-Salpêtrière Hospital, Paris, France
8Department of Biological Haematology, Sorbonne Université, INSERM, Centre de recherche des Cordeliers, AP-HP, Pitié-Salpêtrière Hospital, Paris, FRA
9Department of Pathology, Henri Mondor Hospital, Créteil, France
10Lymphoid Malignancies Unit, Henri Mondor Hospital, Créteil, France
11Department of Clinical Hematology, Sorbonne Université, AP-HP, Pitié-Salpêtrière Hospital, Paris, France

*signifies non-member of ASH